ArticleTranslational oncology2017
Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
Article in Translational oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Pooled it
- Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.The British journal of radiology · 2021Pooled it
- Interim Breast MRI for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer.European journal of breast health · 2026Article
- Article
- Review of Prognostic Significance of Quantitative BPE Measurements.Diagnostics (Basel, Switzerland) · 2026Review
- K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy.Journal of applied clinical medical physics · 2026Article
- Comparison of Contralateral Breast Background Parenchymal Enhancement on MRI Before and After Neoadjuvant Chemotherapy According to Molecular Subtypes in Unilateral Breast Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- TopoTxR: A topology-guided deep convolutional network for breast parenchyma learning on DCE-MRIs.Medical image analysis · 2025Article
- Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.Journal of magnetic resonance imaging : JMRI · 2024Article
- A Diagnostic Dilemma: New Enhancing Suspicious Findings on Breast MRI Following Neoadjuvant Chemotherapy.Journal of breast imaging · 2023Article
- Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response.Tomography (Ann Arbor, Mich.) · 2022Article
- Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.Radiology · 2021Article
- Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI.Journal of personalized medicine · 2021Article
- The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.European journal of radiology · 2021Article
- Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.Breast cancer research : BCR · 2021Article
- Harmonization of Quantitative Parenchymal Enhancement in TJournal of magnetic resonance imaging : JMRI · 2020Article
- Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.Journal of breast imaging · 2020Article
- Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.Tomography (Ann Arbor, Mich.) · 2020Article
- Background parenchymal enhancement on breast MRI: A comprehensive review.Journal of magnetic resonance imaging : JMRI · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo retrospectively investigate the quantitative background parenchymal enhancement (BPE) of the contralateral normal breast in patients with unilateral invasive breast cancer throughout multiple monitoring points of neoadjuvant chemotherapy (NAC) and to further determine whether BPE is associated with tumor response, especially at the early stage of NAC. MATERIALS AND
methodsA total of 90 patients with unilateral breast cancer who then received six or eight cycles of NAC before surgery were analyzed retrospectively. BPE was measured in dynamic contrast-enhanced MRI at baseline and after 2nd, 4th, and 6th NAC, respectively. Correlation between BPE and tumor size was analyzed, and the association between pathologic complete remission (pCR) and BPE was also analyzed.
resultsThe BPE of contralateral normal breast showed a constant reduction throughout NAC therapy regardless of the menopausal status (P<.001 in all). Both the BPEs and the changes of BPE in each of the three monitoring points were significantly correlated with those in tumor size (P<.05 in all), and the reduction of BPE after 2nd NAC had the largest diagnostic value for pCR (AUC=0.726, P<.001), particularly in hormonal receptor (HR)-negative patients (OR=0.243, 95%CI=0.083 to 0.706, P=.009).
conclusionThe BPE of contralateral normal breast had a constant decreased tendency similar to the change of tumor size in NAC. Reduction of BPE at the early stage of NAC was positively associated with pCR, especially in HR-negative status.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.